$359.00
2.72% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US5588681057
Symbol
MDGL

Madrigal Pharmaceuticals, Inc. Stock price

$359.00
+39.13 12.23% 1M
+18.83 5.54% 6M
+50.43 16.34% YTD
+116.91 48.29% 1Y
+285.66 389.50% 3Y
+251.91 235.23% 5Y
+283.75 377.08% 10Y
+40.85 12.84% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+9.50 2.72%
ISIN
US5588681057
Symbol
MDGL
Industry

Key metrics

Basic
Market capitalization
$7.8b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
24.5 | 11.2
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
72.4%
Return on Equity
-61.8%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$317.4m | $696.5m
EBITDA
$-423.8m | $-370.2m
EBIT
$-425.1m | $-323.5m
Net Income
$-391.6m | -
Free Cash Flow
$-401.4m
Growth (TTM | estimate)
Revenue
- | 286.7%
EBITDA
6.6% | 25.5%
EBIT
6.4% | 35.0%
Net Income
11.9% | -
Free Cash Flow
-2.6%
Margin (TTM | estimate)
Gross
96.6%
EBITDA
-133.5% | -53.2%
EBIT
-134.0%
Net
-123.4% | -
Free Cash Flow
-126.5%
More
EPS
$-17.7
FCF per Share
-
Short interest
19.8%
Employees
528
Rev per Employee
$340.0k
Show more

Is Madrigal Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

20x Buy
87%
2x Hold
9%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy
87%
Hold
9%
Sell
4%

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
317 317
-
100%
- Direct Costs 11 11
-
3%
307 307
-
97%
- Selling and Administrative Expenses 522 522
202% 202%
165%
- Research and Development Expense 210 210
26% 26%
66%
-424 -424
7% 7%
-134%
- Depreciation and Amortization 1.31 1.31
126% 126%
0%
EBIT (Operating Income) EBIT -425 -425
6% 6%
-134%
Net Profit -392 -392
12% 12%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about Madrigal Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Madrigal Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT.
Neutral
GlobeNewsWire
5 days ago
CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2025 to 26 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducem...
Neutral
Seeking Alpha
7 days ago
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Soergel - Executive VP & Chief Medical Officer Mardi C. Dier - Executive VP & CFO Tina E.
More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office United States
CEO William Sibold
Employees 528
Founded 2011
Website www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today